missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human FHL2 (aa 132-275) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (95%), Rat (95%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-110702 (PA5-110702. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a member of the four-and-a-half-LIM-only protein family. Family members contain two highly conserved, tandemly arranged, zinc finger domains with four highly conserved cysteines binding a zinc atom in each zinc finger. This protein is thought to have a role in the assembly of extracellular membranes. Also, this gene is down-regulated during transformation of normal myoblasts to rhabdomyosarcoma cells and the encoded protein may function as a link between presenilin-2 and an intracellular signaling pathway. Multiple alternatively spliced variants encoding different isoforms have been identified.
Specifications
Specifications
| Accession Number | Q14192 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 2274 |
| Name | Human FHL2 (aa 132-275) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AAG11; aging-associated gene 11; down-regulated in rhabdomyosarcoma LIM protein; DRAL; Fhl2; FHL-2; four and a half LIM domains 2; four and a half LIM domains protein 2; LIM domain protein DRAL; OTTHUMP00000203164; OTTHUMP00000203168; OTTHUMP00000203169; skeletal muscle LIM-protein 3; SLIM 3; SLIM3; SLIM-3 |
| Common Name | FHL2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction